Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population

Basit Öğe Kaydı
dc.contributor.authorKayilioglu, Hulya
dc.contributor.authorKocak, Ulker
dc.contributor.authorKaraer, Derya Kan
dc.contributor.authorPercin, Emriye F.
dc.contributor.authorSal, Ertan
dc.contributor.authorTekkesin, Funda
dc.contributor.authorGursel, Turkiz
dc.date.accessioned2020-06-25T18:22:51Z
dc.date.available2020-06-25T18:22:51Z
dc.date.issued2017
dc.departmentKırıkkale Üniversitesi
dc.descriptionPinarli, Faruk Guclu/0000-0002-3241-2478; Albayrak, Meryem/0000-0003-2711-5150
dc.description.abstractVincristine is a widely used chemotherapeutic agent in the treatment of childhood malignancies. Neuropathy is the most common adverse effect. CYP3A4 and CYP3A5 enzymes of cytochrome p450 enzyme system are responsible in vincristine metabolism. Genetic polymorphism may alter the vincristine metabolism and the neurotoxicity rate. In this study, distribution of CYP3A5 alleles among Turkish children with malignancies, relation between CYP3A5 genotype and neurotoxicity rates, as well as severity and duration of neuropathy and total vincristine doses were investigated. Patient group consisted of 115 patients (age, 1 to 17 y) with acute lymphoblastic leukemia and solid tumors, who were treated with vincristine consisting chemotherapy protocols. Control group consisted of 50 children without any neurological symptom or disorders. All patient files were reviewed for presence and severeness of neurotoxicity symptoms. Blood samples were obtained and CYP3A5 genotypes were analyzed. Neurotoxicity occurred in 20.8% of patients. Although it was found to occur more frequently after 4 doses of vincristine, and rates were higher in the low-dose vincristine group suggesting other contributing factors. Although neurotoxicity rate in the CYP3A5*1/*3 genotype was 17.6%, it was 21.6% in the CYP3A5*3/*3 genotype and the difference was not statistically significant (P<0.05). This study suggested that vincristine-related neurotoxicity is dose-independent and genotype is not the only causative factor in the occurrence of neurotoxicity in these patients.en_US
dc.description.sponsorshipGazi University Scientific Research Projects UnitGazi University [SBE-01/2011-72]en_US
dc.description.sponsorshipSupported by Gazi University Scientific Research Projects Unit with a project number of SBE-01/2011-72.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1097/MPH.0000000000000910
dc.identifier.endpage462en_US
dc.identifier.issn1077-4114
dc.identifier.issn1536-3678
dc.identifier.issue6en_US
dc.identifier.pmid28697165
dc.identifier.scopus2-s2.0-85023200962
dc.identifier.scopusqualityQ3
dc.identifier.startpage458en_US
dc.identifier.urihttps://doi.org/10.1097/MPH.0000000000000910
dc.identifier.urihttps://hdl.handle.net/20.500.12587/6929
dc.identifier.volume39en_US
dc.identifier.wosWOS:000406231400018
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal Of Pediatric Hematology Oncology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCYP3A5en_US
dc.subjectgenetic polymorphismen_US
dc.subjectneurotoxicity syndromesen_US
dc.subjectvincristineen_US
dc.titleAssociation of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Populationen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.pdf
Boyut:
127.17 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu